Effective October 18, 2023, the 2023-2024 formulations of two COVID-19 vaccines have been added to the ADAP formulary: Comirnaty® (Pfizer) and Spikevax® (Moderna).
An updated (2023-2024 formula) COVID-19 vaccine is recommended for all people with HIV. The virus that causes COVID-19 is always changing, and protection from COVID-19 vaccines and prior COVID-19 infection declines over time. Receiving an updated (2023-2024 formula) COVID-19 vaccine is safe and can restore protection against infections and severe disease. Vaccination is particularly important for people with HIV as they are at increased risk for severe COVID-19 infection and related complications. The COVID-19 vaccine and flu vaccine can be co-administered at the same visit. Ensuring that people with HIV stay up to date with these vaccines is critical, as we all work to protect them and decrease acute illnesses in our community.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. A more detailed Dear Colleagues letter from OA reviewing frequently asked questions about COVID-19, influenza, and respiratory syncytial virus (RSV) vaccines for people with HIV is available on our website: Flu (PDF), COVID-19 (PDF), and RSV Vaccines 2023 (PDF). The ADAP drug formulary has been updated to reflect the addition of COVID-19 vaccines.
If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).
ADAP Branch Chief
California Department of Public Health